Thomas Gad is the Interim Chief Executive Officer of Y-mAbs Therapeutics, Inc., where he has been instrumental in developing innovative cancer treatments. He founded the company back in April 2015, motivated by his daughter’s battle with high-risk neuroblastoma, which adds...

Thomas Gad is the Interim Chief Executive Officer of Y-mAbs Therapeutics, Inc., where he has been instrumental in developing innovative cancer treatments. He founded the company back in April 2015, motivated by his daughter’s battle with high-risk neuroblastoma, which adds a personal touch to his commitment to the business. Thomas holds an MBA from Harvard Business School and has over 12 years of experience in the pharmaceutical industry, which includes roles in business development and senior management. In 2023, his total compensation was about $1,062,097, primarily from his salary and performance-based incentives, reflecting his significant contribution. Interestingly, Gad was appointed interim CEO on April 22, 2022, and has continued to lead the company through challenging times, including a shift in executive leadership now that he’s transitioned to Chief Business Officer. His strategic vision is not just about the science but also about connecting emotionally with the mission of the company, as he dedicates his efforts to making breakthroughs for patients with serious conditions.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Y-mAbs Therapeutics, Inc. CEOs

Y

Thomas Gad

Founder and Ex-CEO of Y-mAbs Therapeutics, Inc.

Education

MBA from Harvard Business School

Field of Expertise

Business & Management - Business Development

Sector of Economy

Healthcare

Born

January 1, 1962 - 63 years ago

CEO of Y-mAbs Therapeutics, Inc. for

1 year 6 months (Apr 2022 - Nov 2023)

Previous Experience

Founder of Y-mAbs Therapeutics, Inc. and has extensive experience in business development and strategy in the biopharmaceutical industry.

Rivals

Competitors/colleagues of Thomas Gad

Holdings

See how much did Thomas Gad make over time.

As of 2023, Thomas Gad owns options to purchase 75,000 shares of Y-mAbs Therapeutics stock as part of his interim CEO compensation. He received this grant after serving as interim CEO and aims to align his interests with those of...

As of 2023, Thomas Gad owns options to purchase 75,000 shares of Y-mAbs Therapeutics stock as part of his interim CEO compensation. He received this grant after serving as interim CEO and aims to align his interests with those of the shareholders. Prior to 2023, he had no vested stock, focusing primarily on performance-based cash incentives that reflected the company’s achievements. His holdings reflect not just personal investment in the company but also aim to foster growth in an innovative space. This move signals his long-term commitment and belief in the company’s future potential, despite the company's stock price fluctuations over the years. During his tenure, his wealth was primarily tied up in a range of compensation rather than direct stock holdings, emphasizing a performance-oriented focus.

Mar 18, 2025

Y

shares

YMAB @ $4.54

Total Stock Sold

$47.34M

YMAB

$47.34M

2,391,956 YMAB shares

What if they kept their stock?

If Thomas Gad didn't sell their stock, today they would have:
Extra YMAB2,391,956 shares worth $99.62M.
This is 110.43% and $52.28M more than what they got when they sold the stock.

Charitable Transactions

YMAB

68,000 shares

YMAB

Recent Charitable Transactions

YMAB

60,000 shares

YMAB

Dec 14, 2021

Charity

YMAB

8,000 shares

YMAB

Dec 13, 2019

Charity

Insider Trading

See recent insider trades of Thomas Gad.

YMAB

$56.54K

YMAB at $5.23/share

Mar 7, 2025

Sale

YMAB

32,000 shares

YMAB

Jan 17, 2025

Received

YMAB

$1.26M

YMAB at $13.22/share

Sep 13, 2024

Sale

YMAB

$841.05K

YMAB at $12.02/share

Jun 10, 2024

Sale

YMAB

$404.39K

YMAB at $12.50/share

May 21, 2024

Sale

YMAB

$64.12K

YMAB at $16.44/share

Mar 5, 2024

Sale

YMAB

22,100 shares

YMAB

Jan 18, 2024

Received

YMAB

$1.00M

YMAB at $6.67/share

Dec 13, 2023

Sale

YMAB

$795.38K

YMAB at $5.30/share

Nov 20, 2023

Sale

YMAB

40,500 shares

YMAB

Jan 17, 2023

Received

Compensation History

See how much did Thomas Gad make over time.

In 2023, Thomas Gad's total compensation was reported at $1,062,097. This amount consisted of a base salary of $664,899, a performance-based bonus of $362,370 for achieving targets, and additional compensation like housing allowance. It's interesting to note that he didn't vest any stock or options this year, focusing on cash-based incentives instead. This structure suggests a streamlined approach to compensation, prioritizing immediate performance and results rather than stock option incentives. The compensation has a clear goal: aligning his interests with those of the shareholders while driving forward the company's mission to improve cancer treatments. His pay reflects accountability and a direct tie to the company’s performance metrics.

Year

2023

Total Compensation

$1.11M

Salary

$664.90K

Board Justification

The compensation philosophy aims to attract, retain, and motivate superior executive talent while aligning executives' interests with those of stockholders through performance-based incentives.

Bonus

$362.37K

Board Justification

Performance-based annual cash incentive compensation based on achieving predetermined performance targets for 2023, resulting in a payout percentage of 109% of the target bonus.

Other

$84.36K

Board Justification

Other compensation includes a monthly housing allowance and accident insurance premiums.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock was vested in 2023 as the focus was on cash compensation and options granted.

Performance Metrics

Performance metrics include financial and operational targets aligned with the company's long-term goals.

Other Y-mAbs Therapeutics, Inc. CEOs

Here are other CEOs of Y-mAbs Therapeutics, Inc.

Dr. Claus Møller

Ex-CEO of Y-mAbs Therapeutics, Inc.

March 2016 - April 2022

Michael Rossi

CEO of Y-mAbs Therapeutics, Inc.

November 2023 - Present